Stanford University School of Medicine, 291 Campus Drive, Stanford, CA 94305, United States.
Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, United States.
Int J Drug Policy. 2022 Apr;102:103617. doi: 10.1016/j.drugpo.2022.103617. Epub 2022 Feb 16.
Opioid use disorder (OUD) is a global public health concern. The standard of care for OUD involves treatment using medications such as buprenorphine, methadone, or naltrexone. No known review exists to assess the contextual factors associated with medication for opioid use disorder (MOUD) in the Arab World. This systematic review serves as an implementation science study to address this research gap and improve the uptake of MOUD in the Arab World.
Systematic searches of Medline, PsycINFO, and EMBASE, and a citation analysis, were used to identify peer-reviewed articles with original data on MOUD in the Arab World. Quality assessment was conducted using the CASP appraisal tools, and main findings were extracted and coded according to the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework.
652 research articles were identified, and 10 met inclusion criteria for final review. Four studies considered health-systems aspects of MOUD administration, such as cost-effectiveness, the motivations for and impact of national MOUD policies, the types of social, political, and scientific advocacy that led to the adoption of MOUD in Arab countries, and the challenges limiting its wide-scale adoption in the Arab World. Six papers considered MOUD at individual and group patient levels by evaluating patient quality of life, addiction severity, patient satisfaction, and patient perspectives on opioid agonist therapy.
Despite financial and geographic barriers that limit access to MOUD in the Arab World, this review found MOUD to be cost-effective and associated with positive health outcomes for OUD patients in the Arab World. MOUD can be successfully established and scaled to the national level in the Arab context, and strong coalitions of health practitioners can lobby to establish MOUD programs in Arab countries. Still, the relative novelty of MOUD in this context precludes an abundance of research to address its long-term delivery in the Arab World.
阿片类药物使用障碍(OUD)是全球公共卫生关注的问题。OUD 的标准治疗包括使用丁丙诺啡、美沙酮或纳曲酮等药物进行治疗。目前尚无已知的综述评估与阿拉伯世界药物治疗阿片类药物使用障碍(MOUD)相关的背景因素。这项系统综述是一项实施科学研究,旨在解决这一研究空白,并提高 MOUD 在阿拉伯世界的采用率。
系统检索 Medline、PsycINFO 和 EMBASE,并进行引文分析,以确定阿拉伯世界 MOUD 的原始数据的同行评审文章。使用 CASP 评估工具进行质量评估,并根据 Reach、Effectiveness、Adoption、Implementation 和 Maintenance(RE-AIM)框架提取和编码主要发现。
确定了 652 篇研究文章,其中 10 篇符合最终审查的纳入标准。四项研究考虑了 MOUD 管理的卫生系统方面,如成本效益、国家 MOUD 政策的动机和影响、导致 MOUD 在阿拉伯国家采用的社会、政治和科学倡导的类型,以及限制其在阿拉伯世界广泛采用的挑战。六篇论文通过评估患者的生活质量、成瘾严重程度、患者满意度和患者对阿片类激动剂治疗的看法,在个体和群体患者层面考虑了 MOUD。
尽管阿拉伯世界存在限制 MOUD 获得的财政和地理障碍,但这项综述发现 MOUD 对阿拉伯世界 OUD 患者具有成本效益,并与积极的健康结果相关。MOUD 可以在阿拉伯背景下成功建立并扩展到国家层面,并且强大的卫生从业者联盟可以游说在阿拉伯国家建立 MOUD 计划。然而,MOUD 在这方面的相对新颖性排除了大量研究来解决其在阿拉伯世界的长期提供问题。